74 results
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
or to regulatory approvals, investigational exemptions, or the procurement, development, research, manufacture, production, packaging, labeling, distribution … ) intermediates, (c) excipients, (d) processing aids, (e) active ingredients, (f) bulk drug product, and (g) packaging and labelling materials and components
8-K
EX-10.1
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
). Following the Closing Date, Mayne may use its trade name on any packaging, leaflets, advertising, or promotional materials used for or in connection … with the Marked Product(s). Effective as of the date on which Mayne changes any packaging leaflets, advertising, or promotional materials used
8-K
EX-2.1
TXMD
TherapeuticsMD Inc
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
, packaging, good manufacturing practices, labeling, advertising, promotional practices, safety surveillance, record keeping and filing of required reports
8-K
EX-2.1
8s5dnjmqhv
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
S-3ASR
EX-1.2
7dp7aum5
4 Mar 21
Automatic shelf registration
12:00am
8-K
EX-1.1
9camhry yi28
16 Feb 21
Entry into a Material Definitive Agreement
8:35am
8-K
EX-99.1
kpev 132vea8zu6p
13 Jan 21
Entry into a Material Definitive Agreement
8:50am
8-K
EX-1.1
tic ys92b3tovb7n2n
27 Nov 20
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-1.1
05s51 blmcu27ec8x5m2
13 Nov 20
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
mtdn1abqkvzib554
14 Sep 20
Regulation FD Disclosure
6:30am
8-K
EX-99.1
7l10gsgr2
23 Jun 20
Regulation FD Disclosure
6:51am
8-K
EX-99.1
nk049vng
13 May 20
Regulation FD Disclosure
7:07am